scholarly journals Acute pulmonary hypertension and short‐term outcomes in severe Covid‐19 patients needing intensive care

2021 ◽  
Author(s):  
Joakim Norderfeldt ◽  
Andreas Liliequist ◽  
Claes Frostell ◽  
Christofer Adding ◽  
Per Agvald ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Intensive Care ◽  
Short Term ◽  
Acute Pulmonary Hypertension

scholarly journals KIDNEY INJURY MOLECULE-1 AS AN EARLY AMIKACIN-INDUCED NEPHROTOXICITY MARKER IN PATIENTS WITH SEPSIS HOSPITALIZED IN THE INTENSIVE CARE UNIT

2019 ◽  
pp. 277-279
Author(s):  
TRISNI UNTARI DEWI ◽  
INSTIATY . ◽  
RUDIANTO SEDONO ◽  
GESTINA ALISKA ◽  
MUHAMMAD KHIFZHON AZWAR ◽  
...  
Keyword(s):  
Intensive Care ◽  
Kidney Injury ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment ◽  
Safe Level ◽  
Study Results ◽  
Early Biomarker ◽  
Kidney Injury Molecule 1 ◽  
Trough Plasma

Objective: This study sought to determine the correlation between trough plasma amikacin concentrations and urinary normalized kidney injurymolecule-1 (KIM-1) concentrations as an early biomarker of nephrotoxicity in patients with sepsis who are hospitalized in an intensive care unit.Methods: In this pilot study, 12 patients with sepsis were treated with amikacin 1000 mg/day between May 2015 and September 2015. The correlationbetween trough plasma amikacin concentrations measured after the third dose and the elevation of urinary normalized KIM-1 concentrations afterthe third amikacin dose relative to the first/second dose was evaluated.Results: In total, three patients had trough plasma amikacin concentrations exceeding the safe level (>10 μg/ml). Furthermore, eight patientsdisplayed higher normalized KIM-1 concentrations after third dose than after the first/second dose; however, there was no correlation betweentrough amikacin concentrations and the elevation of urinary normalized KIM-1 concentrations (r=0.3, p=0.3).Conclusion: The study results illustrated that short-term treatment with an amikacin dose of 1000 mg/day was generally safe in patients with sepsis.

56: INTENSIVE CARE MORTALITY PROGNOSTIC MODEL FOR PEDIATRIC PULMONARY HYPERTENSION

2018 ◽  
Vol 46 (1) ◽  
pp. 28-28
Author(s):  
Emily Balkin ◽  
Matthew Zinter ◽  
Jeffrey Fineman ◽  
Martina Steurer
Keyword(s):  
Pulmonary Hypertension ◽  
Intensive Care ◽  
Prognostic Model

Short-term outcomes in older intensive care unit patients with dementia*

2005 ◽  
Vol 33 (6) ◽  
pp. 1371-1376 ◽  
Author(s):  
Margaret A. Pisani ◽  
Carrie A. Redlich ◽  
Lynn McNicoll ◽  
E Wesley Ely ◽  
Rebecca J. Friedkin ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Short Term

scholarly journals Short-Term Administration of a Cell-Permeable Caveolin-1 Peptide Prevents the Development of Monocrotaline-Induced Pulmonary Hypertension and Right Ventricular Hypertrophy

Circulation ◽  
2006 ◽  
Vol 114 (9) ◽  
pp. 912-920 ◽  
Author(s):  
Jean-François Jasmin ◽  
Isabelle Mercier ◽  
Jocelyn Dupuis ◽  
Herbert B. Tanowitz ◽  
Michael P. Lisanti
Keyword(s):  
Pulmonary Hypertension ◽  
Right Ventricular ◽  
Ventricular Hypertrophy ◽  
Right Ventricular Hypertrophy ◽  
Short Term ◽  
Caveolin 1 ◽  
Term Administration ◽  
A Cell
Sign in / Sign up

Export Citation Format

Share Document